Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098124 · ClinicalTrials.gov registry record · Phase 3
Study of Milnacipran for the Treatment of Fibromyalgia
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
NCT00098124 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 1,200 participants.
The verdict
NCT00098124, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
Study Summary
Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia.
Interventions
- DRUG milnacipran hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00098124
The ClinicalTrials.gov registry entry for NCT00098124 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which milnacipran hydrochloride is the first listed.
NCT00098124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00098124 about?
NCT00098124 is a clinical study titled "Study of Milnacipran for the Treatment of Fibromyalgia". Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor ...
What is the current status of trial NCT00098124?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2004-11. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00098124?
The interventions under investigation include: milnacipran hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00098124?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.